On June 5, 2025, Needham analyst Ami Fadia reiterated a Buy rating for Immuneering (IMRX, Financial). The analyst has maintained the price target at $9.00 USD, which remains unchanged from the prior evaluation.
The decision reflects a consistent outlook for Immuneering (IMRX, Financial), as both the rating and the price target have remained steady. This suggests that the analyst continues to see potential in the company's future performance and value at the given price level.
Investors will find it noteworthy that the price target for Immuneering (IMRX, Financial) has not experienced any percentage change, emphasizing the analyst's confidence in the stability and prospects of the stock within the current market conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Immuneering Corp (IMRX, Financial) is $14.33 with a high estimate of $21.00 and a low estimate of $9.00. The average target implies an upside of 631.29% from the current price of $1.96. More detailed estimate data can be found on the Immuneering Corp (IMRX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Immuneering Corp's (IMRX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
